

# VU Research Portal

## **Response evaluation during targeted therapy: early incorporation of imaging biomarkers**

de Langen, A.J.

2012

### **document version**

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

### **citation for published version (APA)**

de Langen, A. J. (2012). *Response evaluation during targeted therapy: early incorporation of imaging biomarkers*.

### **General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

### **Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

### **E-mail address:**

[vuresearchportal.ub@vu.nl](mailto:vuresearchportal.ub@vu.nl)

## Contents

Chapter 1	Introduction and scope of the thesis	7
Chapter 2	Use of H <sub>2</sub> <sup>15</sup> O PET and DCE-MRI to measure tumor blood flow <i>Oncologist. 2008; 13(6): 631-644</i>	23
Chapter 3	Reproducibility of tumor perfusion measurements using <sup>15</sup> O-labeled water and PET <i>J Nucl Med. 2008; 49(11): 1763-1768</i>	49
Chapter 4	Repeatability of <sup>18</sup> F-FDG uptake measurements in tumors: a meta-analysis <i>Accepted for publication in J Nucl Med</i>	63
Chapter 5	Reproducibility of quantitative <sup>18</sup> F-3'-deoxy-3'-fluorothymidine measurements using positron emission tomography <i>Eur J Nucl Med Mol Imaging. 2009; 36(3): 389-395</i>	83
Chapter 6	First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging <i>Ann Oncol. 2011; 22(3): 559-566</i>	97
Chapter 7	Monitoring response to antiangiogenic therapy in non-small-cell lung cancer using imaging markers derived from PET and dynamic contrast-enhanced MRI <i>J Nucl Med. 2011; 52(1): 48-55</i>	115
Chapter 8	Discussion and future perspectives	133
	Nederlandse samenvatting	147
	Dankwoord	157
	Curriculum Vitae	163
	Publications	167